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Highlights 
x This study tested the observed levels of salivary EBV in 3 MS cohorts 
x The assay was used to define EBV shedding as a reliably detectable level of 
extracellular EBV DNA in saliva 
x Frequency of EBV shedding was found to be similar across the groups, with 20-25% 
of subjects releasing virus on any given sampling date.  
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ABSTRACT  
Background:  
Epstein Barr Virus (EBV) infection is closely associated with multiple sclerosis (MS), but the 
relationship between viral load and disease activity is unclear. This study tested the observed levels 
of salivary EBV in MS, as a first step in investigating this relationship. 
Methods:  
Real-time quantitative PCR (qPCR) was used to measure EBV DNA levels in saliva samples from three 
separate Multiple Sclerosis (MS) patient cohorts. 
Results:  
The qPCR assay was used to delineate EBV shedding, defined here as a reliably detectable level of 
extracellular EBV DNA in saliva. Frequency of EBV shedding was found to be similar across the 
groups, with 20-25% of subjects releasing virus on any given sampling date.  
Diurnal variation in EBV count was tested in one of the cohorts, in which 26% of subjects showed 
more than a 10-fold difference between the highest and lowest EBV levels on a single day. In the 
same cohort, elevated viral levels at one time point did not predict elevated viral levels at a 
subsequent time point. 
Conclusions:  
These results indicate that EBV lytic activity in a subject cannot be inferred from a single measure of 
EBV in saliva. Also, subjects do not appear to be behave constantly as “EBV shedders” or “non-
shedders”. The assay is useful in giving a clear indication of salivary gland EBV lytic activity across a 
patient cohort – for example, in testing anti-viral drugs in MS.  
 
 
BACKGROUND  
Epstein Barr Virus (EBV) infection is the virus most strongly associated with multiple sclerosis (MS) 
(Christensen, 2006; Pender & Burrows, 2014), with almost all MS patients (MSers) found to be 
seropositive for EBV (Bray, Bloomer, Salmon, Bagley, & Larsen, 1983; Wandinger et al., 2000).  
Evidence for a pathogenic role of EBV in MS is supported by elevated EBV antibody titres in MS 
patient cohorts (Farrell et al., 2009; Latham et al., 2016). In one such study (Wandinger et al 2000), 
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antibody response to EBV (IgG) early antigen (EA) was found in 73% of patients with disease 
exacerbations and in none of those with clinically stable disease. Early antigen response is a marker 
of acute viral infection, at which time extensive release of viral particles into saliva (viral shedding) 
occurs (Hadinoto, Shapiro, Sun, & Thorley-Lawson, 2009). Such particles consist of a lipid envelope 
containing virally-encoded glycoproteins, a protein capsid and viral DNA (Perera, Samaranayake, & 
Tsang, 2010). Arguably, increased antibody titres could arguably reflect immune dysregulation 
(Hunter & Hafler, 2000) and may not be linked temporally to viral reactivation. For this reason, 
measurement of EBV levels using qPCR may be preferable to antigen response assays as a measure 
of virus reactivation. One such study showed elevated salivary EBV levels in children with MS (Yea et 
al., 2013), and a recent investigation found detectable salivary EBV to be 20x more frequent in adults 
with relapsing MS compared with healthy controls, although this increase in shedding frequency was 
not found to be statistically significant (Giess et al., 2017). The temporal association between EBV 
release and MS disease activity measured by magnetic resonance imaging (MRI) is unclear. A recent 
investigation demonstrated a negative correlation between MRI activity and EBV titres 4-6 weeks 
before the MRI scan (Latham et al., 2016).  
The purpose of the present study was to establish a reliable protocol for defining and quantifying 
salivary EBV, and then identify the normal patterns of salivary EBV levels in MS. Knowledge of 
expected levels of salivary EBV in MS would ensure that future studies have sufficient statistical 
power to identify the relationship, if any, between viral load and disease activity. A clear association 
between EBV shedding and disease activity would also justify a trial of antiviral agents targeting EBV 
in MS.  
 
 
METHODS 
1. Data sets were derived from three cohorts as defined below: 
 INSPIRE (Isentress Pilot Study in Relapsing MS). This comprised 20 patients with active relapsing MS. 
Samples were taken at monthly intervals over 7 months 
ExIMS (Exercise Intervention for MS trial). This consisted of 120 patients with relapsing MS. Sampling 
was undertaken three times over one year. Four separate samples were taken at 3-hourly intervals 
on each sampling date. 
MEAVIS (Measurement of EBV in Saliva). This consisted of 18 MSers who self-collected weekly 
samples over 3 months 
Use of samples in all three cohorts approved by Ethics committees. 
 
2. Analysis of Samples 
 
All samples were analysed in the same laboratory at the Blizard Institute, Queen Mary University of 
London. 
Approximately 1-2ml of saliva was collected at each sampling interval. DNA was isolated from these 
samples using standard protocols QiaSymphony (robot) SP Virus/Bacteria Mini-kit (Qiagen, Hilden, 
Germany) for the INSPIRE samples and Ambion PureLink 96 kit (Thermo Fisher Scientific, Waltham, 
Mass, USA) for the ExIMS and MEAVIS samples. No adjustment was made to DNA concentration. 
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The QPCR method was validated as part of the INSPIRE clinical trial, and an identical method applied 
to all three cohorts. EBV DNA was detected by a Taqman assay targeted to a non-repeated sequence 
of the EBV polymerase gene (Gallagher et al., 1999) and a pyruvate dehydrogenase (PDH) sequence 
(Bissett et al., 2011) was included as a reference gene in a multiplex PCR. The assay used a Qiagen 
QuantiTect Multiplex PCR Kit with a standard protocol (95°C 15 mins; (95°C 60 s, 60°C 60s) x 40 
cycles, reaction volumes of 25μl, primer and probe concentrations 0.4μM and 0.1μM respectively). 
Patient samples were run in duplicate, and a standard curve was included on each PCR plate using a 
dilution series derived from quantitated EBV DNA (Agilent). The CT (cycle threshold) value was set at 
the midpoint of the exponential phase of the PCR and normalised across PCR runs to give uniformity 
across all PCR runs. The assay returned an absolute copy number of EBV per sample (copies per µl of 
saliva), calculated directly from the standard curve.  
The PDH amplification was used to confirm the presence of genomic DNA but was not used to 
calculate the EBV copy number. A negative amplification of both EBV and PDH may indicate a failed 
PCR or a failed DNA extraction. Analysis of samples was repeated once if both EBV and PDH failed to 
amplify. Analysis was also repeated if one of the two EBV replicates failed to amplify, and samples 
were classed as missing data if this repetition was unsuccessful. 
 
 
RESULTS 
 
1. Reliability of Assay 
  
An important goal of the study was to establish a reliable definition of EBV shedding. In earlier 
studies, the presence of EBV in saliva (at levels of as low as 1 copy per Pl) has been taken to indicate 
viral shedding: this assumption was found to be unreliable in our study. Although low copy numbers 
were detectable with this assay, the analysis was only found to be fully reproducible (with coefficient 
of variation <1.4) for EBV levels above 3 copies/Pl (equivalent CT value >36). 
As cellular remnants are present in saliva, very low titres of EBV DNA sample could be due to the 
presence of cellular DNA in the samples. For this reason, the presence of cellular (genomic) DNA was 
measured in the ExIMS cohort using the PDH primer/probe set. No correlation was found between 
PDH and EBV titres in this cohort (Spearman Rank Correlation, Rs= 0.0457, p=0.33), which suggests 
that EBV detected in these assays was mainly extracellular and due to active viral shedding.  
For the purpose of this assay, shedding was defined as a salivary EBV concentration greater than 5.8 
copies/Pl: this is equivalent to one standard deviation above the median in the ExIMS dataset. This 
level is above the minimum reliable detection limit for this assay, and also minimises the effects of 
cellular remnants in saliva.  
 
 
2. EBV Shedding in MS: comparison of 3 MS cohorts  
 
Table 1 compares salivary EBV in our 3 populations to help predict the expected level of shedding in 
a typical MS population.  
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Population Patients Samples EBV present Shedding 
(>5.8 copies/Pl) 
% of subjects with EBV detected* 
 N N N % N % EBV detected % Shedding % 
INSPIRE 20 87 36 41.4 21 24.1 70.0 45.0 
ExIMS 119 280** 107 38.2 64 22.9 68.6 37.3 
MEAVIS 18 114 43 37.7 24 21.1 61.1 44.4 
 
Table 1.  Number of samples collected per cohort: (sample number, shedding, etc.) 
(* subjects with any positive EBV samples during the study) 
(** number of sampling dates, in which 4 samples were taken within a 24h period) 
 
The results show that 20-25% of subjects were found to be releasing salivary EBV at >5.8 copies/Pl 
(shedding EBV) on a given date. 
 
3. Temporal patterns of salivary EBV levels in the EXIMs population.  
 
In the ExIMS study, sampling occurred in all months of the year, so it was possible to test seasonal 
variation in EBV counts. Cold months were assigned lower scores (January = 1, December & February 
= 2, November & March = 3) and warmer months assigned higher scores (October & April = 4, 
September & May = 5, August & June = 6, July = 7). No correlation found between these scores and 
salivary EBV levels taken in these months (r2 = 0.0038), strongly indicating no seasonal effect. 
In the ExIMS population, sampling at four time points on a single day allowed diurnal variation to be 
measured. Although morning EBV counts were on average >60% higher than afternoon values, in 
10% of samples there was more than a 30-fold difference between maximum and minimum EBV 
counts on a single day. Similarly, 26% of samples showed more than a 10-fold difference between 
maximum and minimum EBV counts.  
 
4. Are some subjects either “shedders” or “non-shedders”? 
 
This analysis investigated whether the distribution of viral load scores was non-random with respect 
to subject. As consecutive high scores 1 month apart could relate to a single shedding episode, this 
was exclusively tested in the ExIMS population in which sample dates were at least 3 months apart. 
The null hypothesis was that there was no difference in subsequent shedding behaviour between 
subjects found to be shedding or not at baseline: 
      21 subjects were found to be shedding at baseline, of whom 8 were shedding 3 months later.  
      73 were not shedding at baseline, of which 16 were found to shedding 3 months later. 
No significant difference was observed between these groups (Fisher’s exact test, p=0.16), 
supporting the null hypothesis: repeat sampling showed that people with MS could not be divided 
into discrete groups of “shedders” and “non-shedders”. 
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DISCUSSION 
 
a. Methodology:  
  
Previous studies have equated detectable EBV with shedding, but this study found the detection of 
low levels of salivary EBV to be unreliable. Additionally, as saliva typically contains a cellular fraction, 
any sample from an EBV positive subject will potentially contain trace levels of intracellular EBV. This 
study applied a threshold level for EBV shedding for the detection of extracellular EBV across 
separate cohorts. 
 
b. EBV shedding across separate MS groups:  
 
The percentage of samples (subjects/date) with EBV levels above the defined shedding threshold 
was found to be very similar across the three cohorts (20-25%). This figure provides an expected 
frequency of EBV shedding in MS samples, which should be useful in future studies.  
Across the three cohorts, between 37% and 45% of subjects were found to be shedding EBV at some 
point, which is similar to the result of a previous study in which 41% of subjects were found to be 
shedding (Hollsberg et al., 2005). An important caveat is that the percentage of subjects found to be 
shedding will increase with increased sampling frequency and study duration; therefore this figure 
should not be used in predicting the necessary sample size in future studies. 
 
c. Variation in EBV counts in individuals:  
 
The present study found that salivary EBV levels in a single subject can vary markedly over short 
periods; 10% of patient sample sets showed a greater than 30-fold difference between the highest 
and lowest EBV counts on a given day. In one previous study, similar variation in copy number was 
observed across samples taken at 3-hourly intervals, although the extent of variation was obscured 
by reporting EBV levels as log copies per ml – leading to the erroneous (and cited) conclusion that 
virus shedding is relatively stable over short periods (Hadinoto et al., 2009; Huynh & Rong, 2012).  
 
Data from the ExIMS study showed that for any given subject, EBV copy number at one time-point 
did not predict the EBV level at a subsequent time point. This echoes the results of a previous study 
that found the distinction between “high shedders” and “low shedders” was a function of variation 
within individuals over time, rather than variation between individuals (Hadinoto et al., 2009).  
 
d. Implications for future studies 
 
To date, it has proved difficult to establish a relationship between MS and EBV, given that around 
95% of most healthy populations are positive compared to about 99% of MSers (Ascherio & Munger, 
2007). The example of clinical poliomyelitis shows that a similarly ubiquitous infectious agent can be 
largely asymptomatic and yet cause a serious condition in some. Therefore, if EBV is found to have a 
pathogenic role in MS, it may be possible to prevent it by eliminating EBV infection completely or by 
blocking the pathway that leads from EBV infection to disease development.  
Although relapses were reported by some of our subjects, the comparison of disease activity and 
EBV copy number was not a primary goal in any of the three studies described here. The logical 
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follow-up to this study is to test whether EBV shedding is related to disease activity across an entire 
cohort, for example, by comparing salivary EBV levels with MRI activity. If salivary EBV levels are 
found to be linked to MS disease activity, it would then be important to test whether EBV antiviral 
drugs can be used to treat or even prevent the disease.   
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